Peer Reviewed Journals In Blood Cancer |OMICS International|Journal Of Leukemia

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Peer Reviewed Journals In Blood Cancer

Peer reviewed journals in lymphoma aims to publish most complete and reliable source of information on the discoveries and current developments in the form of original articles, review articles, case reports, short communications, etc. related to Cancer research and therapy and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide. Anaplastic large cell Blood cancer is frequently associated with the t (2;5)(p23;q35) chromosomal translocation, which gives rise to the fusion gene NPM-ALK. The fusion gene transcript can be readily and sensitively detected by PCR. Until some years ago, BM involvement was considered a rare event in ALCL, due to the subtle nature of the BM involvement and by the difficulty of its detection based on routine morphological examination. An international study performed in a large cohort of uniformly treated ALCL children demonstrated that MDD-positivity detected by PCR at diagnosis in BM or peripheral blood (PB) conferred a relapse risk of about 50%. In addition it’s known that ALK over-expression may induce a host immune reaction, giving rise to autologous anti-ALK antibodies. The authors demonstrated that using MDD and antibody titer, patients could be divided into different biological risk groups with different prognosis. In particular progression-free survival (PFS) was only 28% for patients with low antibody titer and MDD-positive, compared to 93% for patients with high antibody titer and MDD-negative (P<0.0001). In the current ALCL international protocol, taking into account only clinical parameter such as mediastinal, visceral or skin involvement for risk stratification, the 3 yrs PFS was 58% for patients with clinical highrisk features vs 88% for standard risk patients. Thus the combination of MDD and antibody titer represents a new prognostic indicator that may be considered in the design of new ALCL trials. Minimal Disseminated Disease in Pediatric Non-Hodgkin Lymphoma (Lara Mussolin)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on March, 2021